Abstract
Patients afflicted with moderate to severe psoriasis experience a reduction in the quality of life. They not only suffer the aggravation associated with the pain, itchiness, and bleeding of the psoriatic lesions, but also experience a negative impact on their daily functions and social well-being. Unfortunately, traditional therapeutic measures have not been effective enough in treating individuals suffering from moderate to severe forms of psoriasis. Most of the conventional medications have produced at best only partial responses. However, the recent chimeric monoclonal TNF-α inhibiting antibody, infliximab, has been proven effective for the treatment of patients with moderate to severe psoriasis. Most patients treated with infliximab have shown rapid and remarkable improvement in the clinical manifestations of the disease. This article will closely examine the efficacy and safety of infliximab through the analysis of past case reports and clinical trials.
Keywords: tumor necrosis factor alpha, inflammatory response, Psoriasis Area and Severity Index (PASI), Aminotransferase, infliximab
Reviews on Recent Clinical Trials
Title: A Review of the Treatment of Psoriasis with Infliximab
Volume: 1 Issue: 3
Author(s): Theodora Vamvouris and Suhail Hadi
Affiliation:
Keywords: tumor necrosis factor alpha, inflammatory response, Psoriasis Area and Severity Index (PASI), Aminotransferase, infliximab
Abstract: Patients afflicted with moderate to severe psoriasis experience a reduction in the quality of life. They not only suffer the aggravation associated with the pain, itchiness, and bleeding of the psoriatic lesions, but also experience a negative impact on their daily functions and social well-being. Unfortunately, traditional therapeutic measures have not been effective enough in treating individuals suffering from moderate to severe forms of psoriasis. Most of the conventional medications have produced at best only partial responses. However, the recent chimeric monoclonal TNF-α inhibiting antibody, infliximab, has been proven effective for the treatment of patients with moderate to severe psoriasis. Most patients treated with infliximab have shown rapid and remarkable improvement in the clinical manifestations of the disease. This article will closely examine the efficacy and safety of infliximab through the analysis of past case reports and clinical trials.
Export Options
About this article
Cite this article as:
Vamvouris Theodora and Hadi Suhail, A Review of the Treatment of Psoriasis with Infliximab, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250122
DOI https://dx.doi.org/10.2174/157488706778250122 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Evolving Novel Chemical Entities for Management of Benign Prostatic Hyperplasia#
Mini-Reviews in Medicinal Chemistry The Cancer Related Thrombotic Tendency in Sepsis
Current Drug Targets A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design The Impact of Hypertension in Hemodialysis Patients
Current Hypertension Reviews Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Organocatalyzed Heterocyclic Transformations In Green Media: A Review
Current Organocatalysis Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology Cancer-Targeting Multifunctionalized Gold Nanoparticles in Imaging and Therapy
Current Medicinal Chemistry Editorial: [Hot Topic: Antidotes and Rescue Therapies]
Current Pharmaceutical Biotechnology Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Status of Herbal Medicines in the Treatment of Diabetes: A Review
Current Diabetes Reviews Flare-Up Phenomenon of Intradermal Test with Anaphylactic Reaction to Paracetamol (Acetaminophen)
Recent Patents on Inflammation & Allergy Drug Discovery Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Endocrine, Metabolic & Immune Disorders - Drug Targets